Search

Your search keyword '"Isophane Insulin, Human"' showing total 2 results
Start Over Descriptor "Isophane Insulin, Human" Journal diabetologia
2 results on '"Isophane Insulin, Human"'

1. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients

Author

Peter Oturai, Bo Feldt-Rasmussen, K. V. Hendriksen, and T. Jensen

Subjects
medicine.medical_specialty, Outpatient Clinics, Hospital, Patient Dropouts, Time Factors, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Insulin, Isophane, NPH insulin, Type 2 diabetes, Insulin Detemir, Weight loss, Internal medicine, Diabetes mellitus, Insulin, Regular, Human, Weight Loss, Internal Medicine, medicine, Outpatient clinic, Humans, Hypoglycemic Agents, Fluid Shifts, Insulin detemir, Aged, Cross-Over Studies, business.industry, Insulin, Sodium, Extracellular Fluid, Middle Aged, Water-Electrolyte Balance, medicine.disease, Insulin, Long-Acting, Isophane Insulin, Human, Endocrinology, Diabetes Mellitus, Type 2, Lean body mass, Body Composition, medicine.symptom, business, medicine.drug, Glomerular Filtration Rate
Abstract

In type 2 diabetic patients, insulin detemir (B29Lys(e-tetradecanoyl),desB30 human insulin) induces less weight gain than NPH insulin. Due to the proposed reduction of tubular action by insulin detemir, type 2 diabetic patients should have increased urinary sodium excretion, thereby reducing extracellular volume and body weight when changed from NPH insulin to insulin detemir. In a randomised, open-labelled, two-way crossover study of 24 patients with type 2 diabetes, patients were first treated with NPH insulin or insulin detemir for 8 weeks. Thereafter, they were changed to the other insulin for 8 weeks. In a third 1 week period, they were changed back to the first insulin. At the end of 8 weeks, body weight was reduced by 0.8 ± 0.2 kg (mean ± SEM) on insulin detemir compared with NPH insulin (p

Published
2011

2. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients.

Author

Hendriksen KV, Jensen T, Oturai P, and Feldt-Rasmussen B

Subjects
Aged, Body Composition drug effects, Cross-Over Studies, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 urine, Extracellular Fluid drug effects, Fluid Shifts drug effects, Glomerular Filtration Rate drug effects, Humans, Hypoglycemic Agents therapeutic use, Insulin Detemir, Insulin, Isophane therapeutic use, Insulin, Long-Acting therapeutic use, Insulin, Regular, Human therapeutic use, Isophane Insulin, Human, Middle Aged, Outpatient Clinics, Hospital, Patient Dropouts, Sodium metabolism, Time Factors, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents adverse effects, Insulin, Isophane adverse effects, Insulin, Long-Acting adverse effects, Insulin, Regular, Human adverse effects, Sodium urine, Water-Electrolyte Balance drug effects, Weight Loss drug effects
Abstract

Aims/hypothesis: In type 2 diabetic patients, insulin detemir (B29Lys(ε-tetradecanoyl),desB30 human insulin) induces less weight gain than NPH insulin. Due to the proposed reduction of tubular action by insulin detemir, type 2 diabetic patients should have increased urinary sodium excretion, thereby reducing extracellular volume and body weight when changed from NPH insulin to insulin detemir., Methods: In a randomised, open-labelled, two-way crossover study of 24 patients with type 2 diabetes, patients were first treated with NPH insulin or insulin detemir for 8 weeks. Thereafter, they were changed to the other insulin for 8 weeks. In a third 1 week period, they were changed back to the first insulin., Results: At the end of 8 weeks, body weight was reduced by 0.8 ± 0.2 kg (mean ± SEM) on insulin detemir compared with NPH insulin (p < 0.01). After insulin detemir treatment, we also observed a significant reduction of lean body mass (0.8 ± 0.2 kg, p < 0.05) and a non-significant reduction of extracellular volume (0.8 ± 0.5 l/1.73 m², p = 0.14). The weight loss occurred after as early as 1 week (0.8 ± 0.2 kg, p < 0.001), with a simultaneous and transient increase of urinary sodium excretion (p = 0.07)., Conclusions/interpretation: Insulin detemir induces significant and sustained weight loss, which is first observed at 1 week after changing from NPH insulin. The initial weight loss seems to be related to changes in fluid volume and may reflect changed insulin action in the kidneys.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results